Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ES-3000 by Escend Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
ES-3000 is under clinical development by Escend Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Data Insights
ES-3000 by Escend Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
ES-3000 is under clinical development by Escend Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...